Berekening van kosten na een beroerte en kosteneffectiviteit van 'stroke units' en van secundaire preventie, zoals aanbevolen in de herziene CBO-richtlijn 'beroerte'

Translated title of the contribution: Calculation of costs and cost effectiveness of stroke units and of secondary prevention in patients after a stroke, as recommended in the revised CBO guideline 'stroke'

Louis Niessen, D. W J Dippel, M. Limburg

Research output: Contribution to journalArticle

Abstract

Objective. Economic analyses have been part of the revision of the Dutch multi-disciplinary stroke guidelines. We evaluated the recommendations on stroke units and prevention of stroke recurrencies in terms of medical costs and health effects among stroke patients. Design. Cost calculation. Method. Mathematical modelling of medical costs per patient and costs per life year gained without severe stroke (Rankin score (> 3)), by age and sex for each guideline. Results. Lifetime costs of stroke depended on age and sex and vary between 84,000 and 292,000 Dutch guilders (HFL). The cost-effectiveness of stroke units decreases with age and varies between HFL 37,000 and HFL 60,200 with a large uncertainty range. Four of seven options in secondary prevention were cost-effective by previously established criteria (<HFL 40,000 per year gained without severe disease). Acetylsalicylic acid remained the drug of choice for monotherapy with dipyridamol as a second choice in patients without atrial fibrillation. Clopidogrel was not cost-effective at the current cost level. Anticoagulation after stroke in case of atrial fibrillation was cost-effective. Conclusions. Given a short hospital stay stroke units can be as affective as other hospital interventions. Acetylsalicylic acid is the most cost effective monotherapy for secondary prevention.

Original languageDutch
Pages (from-to)1959-1964
Number of pages6
JournalNederlands Tijdschrift voor Geneeskunde
Volume144
Issue number41
StatePublished - Oct 7 2000
Externally publishedYes

Fingerprint

Secondary Prevention
Cost-Benefit Analysis
Stroke
Guidelines
Costs and Cost Analysis
clopidogrel
Atrial Fibrillation
Aspirin
Health Care Costs
Uncertainty
Length of Stay
Economics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{33ae752987824afc8c148939471280dd,
title = "Berekening van kosten na een beroerte en kosteneffectiviteit van 'stroke units' en van secundaire preventie, zoals aanbevolen in de herziene CBO-richtlijn 'beroerte'",
abstract = "Objective. Economic analyses have been part of the revision of the Dutch multi-disciplinary stroke guidelines. We evaluated the recommendations on stroke units and prevention of stroke recurrencies in terms of medical costs and health effects among stroke patients. Design. Cost calculation. Method. Mathematical modelling of medical costs per patient and costs per life year gained without severe stroke (Rankin score (> 3)), by age and sex for each guideline. Results. Lifetime costs of stroke depended on age and sex and vary between 84,000 and 292,000 Dutch guilders (HFL). The cost-effectiveness of stroke units decreases with age and varies between HFL 37,000 and HFL 60,200 with a large uncertainty range. Four of seven options in secondary prevention were cost-effective by previously established criteria (<HFL 40,000 per year gained without severe disease). Acetylsalicylic acid remained the drug of choice for monotherapy with dipyridamol as a second choice in patients without atrial fibrillation. Clopidogrel was not cost-effective at the current cost level. Anticoagulation after stroke in case of atrial fibrillation was cost-effective. Conclusions. Given a short hospital stay stroke units can be as affective as other hospital interventions. Acetylsalicylic acid is the most cost effective monotherapy for secondary prevention.",
author = "Louis Niessen and Dippel, {D. W J} and M. Limburg",
year = "2000",
month = "10",
day = "7",
language = "Dutch",
volume = "144",
pages = "1959--1964",
journal = "Nederlands Tijdschrift voor Geneeskunde",
issn = "0028-2162",
publisher = "Bohn Stafleu van Loghum",
number = "41",

}

TY - JOUR

T1 - Berekening van kosten na een beroerte en kosteneffectiviteit van 'stroke units' en van secundaire preventie, zoals aanbevolen in de herziene CBO-richtlijn 'beroerte'

AU - Niessen, Louis

AU - Dippel, D. W J

AU - Limburg, M.

PY - 2000/10/7

Y1 - 2000/10/7

N2 - Objective. Economic analyses have been part of the revision of the Dutch multi-disciplinary stroke guidelines. We evaluated the recommendations on stroke units and prevention of stroke recurrencies in terms of medical costs and health effects among stroke patients. Design. Cost calculation. Method. Mathematical modelling of medical costs per patient and costs per life year gained without severe stroke (Rankin score (> 3)), by age and sex for each guideline. Results. Lifetime costs of stroke depended on age and sex and vary between 84,000 and 292,000 Dutch guilders (HFL). The cost-effectiveness of stroke units decreases with age and varies between HFL 37,000 and HFL 60,200 with a large uncertainty range. Four of seven options in secondary prevention were cost-effective by previously established criteria (<HFL 40,000 per year gained without severe disease). Acetylsalicylic acid remained the drug of choice for monotherapy with dipyridamol as a second choice in patients without atrial fibrillation. Clopidogrel was not cost-effective at the current cost level. Anticoagulation after stroke in case of atrial fibrillation was cost-effective. Conclusions. Given a short hospital stay stroke units can be as affective as other hospital interventions. Acetylsalicylic acid is the most cost effective monotherapy for secondary prevention.

AB - Objective. Economic analyses have been part of the revision of the Dutch multi-disciplinary stroke guidelines. We evaluated the recommendations on stroke units and prevention of stroke recurrencies in terms of medical costs and health effects among stroke patients. Design. Cost calculation. Method. Mathematical modelling of medical costs per patient and costs per life year gained without severe stroke (Rankin score (> 3)), by age and sex for each guideline. Results. Lifetime costs of stroke depended on age and sex and vary between 84,000 and 292,000 Dutch guilders (HFL). The cost-effectiveness of stroke units decreases with age and varies between HFL 37,000 and HFL 60,200 with a large uncertainty range. Four of seven options in secondary prevention were cost-effective by previously established criteria (<HFL 40,000 per year gained without severe disease). Acetylsalicylic acid remained the drug of choice for monotherapy with dipyridamol as a second choice in patients without atrial fibrillation. Clopidogrel was not cost-effective at the current cost level. Anticoagulation after stroke in case of atrial fibrillation was cost-effective. Conclusions. Given a short hospital stay stroke units can be as affective as other hospital interventions. Acetylsalicylic acid is the most cost effective monotherapy for secondary prevention.

UR - http://www.scopus.com/inward/record.url?scp=0034619067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034619067&partnerID=8YFLogxK

M3 - Article

C2 - 11048560

AN - SCOPUS:0034619067

VL - 144

SP - 1959

EP - 1964

JO - Nederlands Tijdschrift voor Geneeskunde

JF - Nederlands Tijdschrift voor Geneeskunde

SN - 0028-2162

IS - 41

ER -